The addition of 786O cancer cells led to an increase in MMP9, Gro-α, IL-8, IL-6, HB-EGF, and VEGF-A; and the addition of ccRCC PBMCs led to an increase in PDGF-BB and IL-1β as well as a further increase in MMP-9, Gro-α, IL-8, IL-6, and CCL-2 despite cabozantinib treatment. This evidence concerns the gene CCL2 and nonpapillary renal cell carcinoma.